The pulse of drug development for Alzheimer's disease.
Therapies that are believed to target the underlying mechanisms of Alzheimer's disease have now reached human clinical trials, with the number of agents in late stage development having increased dramatically in recent years. Primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of Alzheimer's disease, and tau protein which, when hyperphosphorylated, results in the formation of neurofibrillary tangles of paired helical filaments, also believed to be involved in the pathogenesis of Alzheimer's disease. In this review, the current status of Alzheimer's Disease therapies under study is discussed, including the scientific basis for each strategy.
Rafii
Michael S
MS
Alzheimer's Disease Cooperative Study, Attending Neurologist, Shiley-Marcos Alzheimer's Disease Research Center, University of California, San Diego, USA. mrafii@ucsd.edu
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000276:immunology; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D016229:Amyloid beta-Peptides / Q000187:drug effects*; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005227:Fatty Acids / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D007211:Indoles / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000627:therapeutic use; D014611:Vaccination; D016875:tau Proteins / Q000187:drug effects*
D016229:Amyloid beta-Peptides; D000975:Antioxidants; D005227:Fatty Acids; D007211:Indoles; D018696:Neuroprotective Agents; D018377:Neurotransmitter Agents; D016875:tau Proteins; D053829:Amyloid Precursor Protein Secretases; C010119:latrepirdine